Preferred frequencies and waveforms for spinal cord stimulation in patients with complex regional pain syndrome: A multicentre, double-blind, randomized and placebo-controlled crossover trial

被引:99
|
作者
Kriek, N. [1 ]
Groeneweg, J. G. [1 ]
Stronks, D. L. [1 ]
de Ridder, D. [2 ]
Huygen, F. J. P. M. [1 ]
机构
[1] Erasmus MC Univ Med Ctr Rotterdam, Ctr Pain Med, Rotterdam, Netherlands
[2] Univ Otago, Dunedin Sch Med, Sect Neurosurg, Dept Surg Sci, Dunedin, New Zealand
关键词
BACK SURGERY SYNDROME; CONVENTIONAL MEDICAL-MANAGEMENT; ELECTRICAL INHIBITION; LIMB; MECHANISMS;
D O I
10.1002/ejp.944
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Conventional tonic spinal cord stimulation (SCS) is an effective treatment for patients with therapy-resistant complex regional pain syndrome (CRPS). Although the therapeutic effect of SCS can diminish over time due to tolerance, pain control can be regained by changing the pulse width and the amplitude and/or by increasing the stimulation frequency. This multicentre, double-blind, randomized and placebo-controlled crossover trial was conducted to investigate whether more effective pain reduction is achieved with different frequencies (trial registration, current controlled trials, ISRCTN 36655259). Methods: The investigated settings are as follows: standard 40, 500, 1200 Hz, burst and placebo stimulation. All five were programmed in random order during the 10-week crossover period (2 weeks/setting). The primary outcome parameters were scores on the visual analogue scale (VAS), McGill Pain Questionnaire (MPQ) and the Global Perceived Effect (GPE); at the end of the crossover period, patients decided which SCS setting they preferred. A linear mixed models analysis was performed in 29 patients who completed the crossover trial. Results: Significant pain reduction and GPE satisfaction was achieved with four SCS settings compared with placebo stimulation, and these four settings did not differ significantly from each other. Standard stimulation was preferred by 48% of the patients, while 52% preferred non-standard stimulation. Other than pain reduction, factors such as user-friendliness, comfort and recharging time may have influenced the patient's final decision for the preferred stimulation setting. Conclusions: Apparently, for various reasons, patients have a preference for different SCS setting. Therefore, future neuromodulation should aim to implement customized individual patient care by incorporating all stimulation options in one device. Significance: This study demonstrates that standard frequency SCS is an effective therapy for patients with CRPS. However, it also demonstrates that patients can often gain better pain reduction with non-standard frequencies of SCS. Furthermore, it shows that the preferred stimulation setting is not solely driven by the amount of pain reduction, but is also influenced by which stimulation setting feels most comfortable and provides the best user-friendliness. Therefore, we strive to maximize the therapeutic effects of SCS in as many patients as possible. This can be achieved with customized individual patient care by incorporating the various frequencies and waveforms into one single device.
引用
收藏
页码:507 / 519
页数:13
相关论文
共 50 条
  • [31] Lumbar Sympathetic Blockade in Children with Complex Regional Pain Syndromes A Double Blind Placebo-controlled Crossover Trial
    Meier, Petra M.
    Zurakowski, David
    Berde, Charles B.
    Sethna, Navil F.
    ANESTHESIOLOGY, 2009, 111 (02) : 372 - 380
  • [32] A DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER TRIAL WITH NICERGOLINE IN PATIENTS WITH SENILE DEMENTIA
    ARRIGO, A
    MOGLIA, A
    BORSOTTI, L
    MASSARINI, M
    ALFONSI, E
    BATTAGLIA, A
    SACCHETTI, G
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 1982, 2 (04) : 33 - 41
  • [33] Treatment of chronic constipation with colchicine: Randomized, double-blind, placebo-controlled, crossover trial
    Verne, GN
    Davis, RH
    Robinson, ME
    Gordon, JM
    Eaker, EY
    Sninksy, CA
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (05): : 1112 - 1116
  • [34] Improvement of erectile function with Prelox: a randomized, double-blind, placebo-controlled, crossover trial
    R Stanislavov
    V Nikolova
    P Rohdewald
    International Journal of Impotence Research, 2008, 20 : 173 - 180
  • [35] Double-blind, crossover, placebo-controlled trial of bromocriptine in patients with sleep bruxism
    Lavigne, GJ
    Soucy, JP
    Lobbezoo, F
    Manzini, C
    Blanchet, PJ
    Montplaisir, JY
    CLINICAL NEUROPHARMACOLOGY, 2001, 24 (03) : 145 - 149
  • [36] Tolcapone in Obsessive Compulsive Disorder: A Randomized Double-Blind Placebo-Controlled Crossover Trial
    Grant, Jon
    Chamberlain, Samuel
    NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 312 - 313
  • [37] Intraoperative acupuncture for posttonsillectomy pain: A randomized, double-blind, placebo-controlled trial
    Tsao, Gabriel J.
    Messner, Anna H.
    Seybold, Jeannie
    Sayyid, Zahra N.
    Cheng, Alan G.
    Golianu, Brenda
    LARYNGOSCOPE, 2015, 125 (08): : 1972 - 1978
  • [38] Improvement of erectile function with Prelox: a randomized, double-blind, placebo-controlled, crossover trial
    Stanislavov, R.
    Nikolova, V.
    Rohdewald, P.
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2008, 20 (02) : 173 - 180
  • [39] Supplemental Dietary Nitrate for COPD: a Randomized, Double-blind, placebo-controlled, Crossover Trial
    Kerley, C. P.
    Cahill, K.
    Bolger, K.
    Fennell, K.
    O'Brien, A.
    McGowan, A.
    Burke, C.
    Faul, J. L.
    Cormican, L. J.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2013, 182 : S440 - S440
  • [40] Atomoxetine on neurogenic orthostatic hypotension: a randomized, double-blind, placebo-controlled crossover trial
    Mwesigwa, Naome
    Vernetti, Patricio Millar
    Kirabo, Annet
    Black, Bonnie
    Ding, Tan
    Martinez, Jose
    Palma, Jose-Alberto
    Biaggioni, Italo
    Kaufmann, Horacio
    Shibao, Cyndya A.
    CLINICAL AUTONOMIC RESEARCH, 2024, 34 (06) : 561 - 569